BriaCell Therapeutics Corp.
BCT.TO
TSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -16.60M | -4.79M | -6.00M | -12.61M | -13.19M |
| Total Depreciation and Amortization | 106.70K | 83.80K | 15.20K | 15.20K | 15.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.75M | -26.47M | -26.84M | -16.56M | -10.71M |
| Change in Net Operating Assets | 4.77M | 7.05M | 1.81M | -2.11M | -3.92M |
| Cash from Operations | -23.48M | -24.13M | -31.01M | -31.26M | -27.81M |
| Capital Expenditure | -456.80K | -456.80K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -300.00K | -225.00K | -225.00K | -- | -- |
| Cash from Investing | -756.80K | -681.80K | -225.00K | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.38M | 4.42M | 4.00M | 4.00M | 4.00M |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16.38M | 4.42M | 4.00M | 4.00M | 4.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.85M | -20.39M | -27.23M | -27.26M | -23.81M |
